Press release
Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share
Read moreCreating the future in peptides
We lead innovation in peptide API’s to the benefit of millions of patients
Contact usMarket leader in peptide API manufacturing and services
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) supporting pharmaceutical and biotech companies in the development and manufacturing of proprietary and generic active pharmaceutical ingredients (API).
PolyPeptide publishes the invitation to its extraordinary general meeting of shareholders on 26 October 2026
2 Oct 2026 - Baar, 2 October 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, published the invitation to its extraordinary general […]
Read moreSamsung Peptide AG publishes offer prospectus for public tender offer for PolyPeptide Group AG
31 Aug 2026 - Baar, 31 August 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that Samsung Peptide AG, a […]
Read more